FOXN3-AS1: A Candidate Prognostic Marker and Epigenetic Target with Immunotherapeutic Implications in Acute Myeloid Leukemia
Our candidate approach identifies FOXN3-AS1 as a prognostic indicator of survival in AML with a potential immune-related role. The preliminary observations we made on FOXN3-AS1/DNMT1 crosstalk warrant more in-depth invested immunotherapeutic approaches in AML.
Authors
- Fangfang Ge
- Xiaoli Huang (ORCID: https://orcid.org/0000-0001-9628-5618)
- Markus Essler
- Matthias Schmid (ORCID: https://orcid.org/0000-0002-0788-0317)
- Tikam Chand Dakal (ORCID: https://orcid.org/0000-0002-9248-7391)
- Ulrich Jaehde (ORCID: https://orcid.org/0000-0002-2493-7370)
- Peng Chen (ORCID: https://orcid.org/0000-0002-9293-1552)
- Yulu Wang (ORCID: https://orcid.org/0000-0002-8320-3529)
- Zifeng Wang (ORCID: https://orcid.org/0000-0001-7400-5224)
- Amit Sharma (ORCID: https://orcid.org/0000-0002-3836-5617)
- Ingo G. H. Schmidt-Wolf (ORCID: https://orcid.org/0000-0002-5655-0867)
Institutions
- Shangrao Normal University (CN)
- University of Bonn (DE)
- Zimmer Biomet (Netherlands) (NL)
- University Hospital Bonn (DE)
- Institut für Medizinische Biometrie, Informatik und Epidemiologie (DE)
- Integrated Oncology (United States) (US)
- Zimmer Biomet (Germany) (DE)
- First People's Hospital of Chongqing (CN)
- Mohanlal Sukhadia University (IN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2024-10-14
- DOI
- https://doi.org/10.2174/0109298673311108240926062214
- Citations
- 4
- Primary Topic
- FOXO transcription factor regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.94